A trial exploring ... the two doses of semaglutide were comparable, while around a third of patients treated with 7.2mg achieved more than 25% weight loss. "Results from STEP UP further strengthen ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

When measured by traditional weight loss ... in the STEP 4 trial, 2 patients in the treatment and placebo groups were required to increase their physical activity by 150 minutes per week.

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...

Studies have shown that Ozempic, the popular weight-loss drug ... that those who took low doses of semaglutide—the generic form of Ozempic—for nine weeks experienced significantly greater ...

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

Experts say it’s not yet clear how safe these drugs are for people who don’t need to lose weight ... NIH researcher who is leading a 20-week trial of semaglutide for alcohol use disorder ...